Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: Comparison with heparin and hirudin in a rabbit thrombosis model

Coronary Artery Disease

Volumn 7, Issue 12, 1996, Pages 903-909

  Kornowski, Ran ^a,c   Eldor, Amiram ^a   Werber, Moshe M ^b   Ezov, Nathan ^b   Zwang, Ety ^a   Nimrod, Abraham ^b   Chernine, Airine ^a   Finkelstein, Ariel ^a   Panet, Amos ^b   Laniado, Shlomo ^a   Keren, Gad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Bio Technology General   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Factor Xa; Thrombolysis; Thrombosis; Tissue type plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; HIRUDIN; LYSINE ACETYLSALICYLATE; THROMBIN; UNCLASSIFIED DRUG; YAGIN;

ACUTE HEART INFARCTION; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; DISEASE MODELS, ANIMAL; FACTOR XA; HEPARIN; HIRUDIN THERAPY; LEECHES; MYOCARDIAL REPERFUSION; PARTIAL THROMBOPLASTIN TIME; RABBITS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0030498768     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199612000-00005     Document Type: Review

References (27)

1. Fuster V, Badimon L, Chesebro J: The pathogenesis of coronary artery disease and the acute coronary syndromes. Parts I and II. N Engl J Med 1992, 326:242-250 and 310-318.
2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. W Engl J Med 1980, 303:897-902.
3. Davies MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990, 82 (suppl II):II38-II46.
4. Coller BS: Platelet and thrombolytic therapy. N Engl J Med 1990, 322:33-42.
5. Haskel EJ, Prager NA, Sobel BE, Abendchein DR: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991, 83:1048-1056.
6. Heras M, Chesebro JH, Penny WJ, Baily KR, Badimon L, Fuster V: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989, 79:657-665.
7. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS: Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991, 84:1741-1748.
8. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Plow EF, Topol E: Superiority of selective factor Xa inhibition versus direct thrombin antagonism in facilitating rt-PA-induced thrombolysis in the canine model. Circulation 1993, 88 (suppl I):I545.
9. Vlasuk GP, Ramjil D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, et al.: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors Anistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991, 65:257-262.
10. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992, 85:805-815.
11. Mellot MJ, Holahan MA, Lynch JJ, Vlasuk GP, Dunwiddie CT: Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant anistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res 1992, 70:1152-1160.
12. Werber MM, Zeelon E, Levanon A, Goldberg M, Greenstein LA, Haim B, et al.: Yagin, a leech-derived FXa inhibitor, expressed in and recovered from E. coli: anti-thrombotic patency in vitro and in vivo [abstract]. Thromb Haemost 1995, 73:1312.
13. Hanson SR, Harker LA, Levanon A, Panet A, Werber MM: Inhibition of factor Xa in baboon thrombosis models [abstract]. Thromb Haemost 1995, 73:1311.
14. Gold HK, Yasuda T, Jang IK, Guerrero JL, Fallon JT, Leibach RC: Animal models for arterial thrombolysis and prevention of reocclusion. Circulation 1991, 83 (suppl IV):IV26-IV40.
15. Brill-Edwards P, Van Ryn-MoKenna J, Cai L, Ofosu FA, Buchanan MR: Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. Thromb Haemost 1992, 68:424-427.
16. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchessi BR: High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 1993, 21:502-510.
17. Colman RW, Hirsh J, Marder VJ, Salzman EW: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Third Edition. J.B. Lippincott Company; 1994:193-196.
18. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993, 91:1877-1883.
19. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS: Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991, 84:1741-1748.
20. Nicolini FA, Lee P, Zajkowski B, Plow EF: Selective inhibition of factor Xa and prothrombimase complex during thrombolysis prevents coronary rethrombosis. Circulation 1994, 90 (suppl I):I344.
21. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolytic inhibitor. J Biol Chem 1995, 270:14477-14484.
22. Weitz JI, Huboda M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
23. Nicolini FA, Lee P, Rios G, Marchant KK, Topol EJ: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994, 89:1802-1809.
24. Collen D, Lijnen HR, Gold HK: Towards better thrombolytic therapy. Prog Cardiovasc Dis 1991, 34:101-112.
25. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673-682.
26. Bush LR, Buja LM, Samowitz Q, Rude RE, Wathen M, Tilton GD, et al.: Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Circ Res 1983, 53:248-263.
27. Van de Werf F, Arnold AER: Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 1988, 297:1374-1379.